Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease

Haematologica

Volumn 94, Issue 7, 2009, Pages 1029-1032

  Girnius, Saulius ^a   Seldin, David C ^a   Skinner, Martha ^a   Finn, Kathleen T ^a   Quillen, Karen ^a   Doros, Gheorghe ^a,b   Sanchorawala, Vaishali ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c Section of Hematology/Oncology   (United States)

Author keywords

AL amyloidosis; Liver disease; Stem cell transplantation

Indexed keywords

ALKALINE PHOSPHATASE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; THALIDOMIDE;

ADULT; AGED; AL AMYLOIDOSIS; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 67650761109     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.001925     Document Type: Article

References (22)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol 1991;22:904-7.
3. Kyle RA GM. Primary systemic amylodiosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-9.
4. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.
5. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82:291-8.
6. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-8.
7. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.
8. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999;93:1062-6.
9. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007;19:136-41.
10. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140:85-93.
11. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 2007;14:261-9.
12. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with highdose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.
13. Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339-43.
14. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319-28.
15. Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, Connors LH, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007;56:3858-68.
16. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001;134:746-53.
17. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
18. Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85:73-80.
19. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, et al. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature. Amyloid 2009;16:2.
20. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
21. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105: 2949-51.
22. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357:1083-93.